Mechanisms navigating the TGF-βpathway in prostate cancer

作     者：Zheng Cao Natasha Kyprianou 

作者机构：Department of ToxicologyUniversity of Kentucky College of MedicineLexingtonKYUSA Department of UrologyUniversity of Kentucky College of MedicineLexingtonKYUSA Department of PathologyUniversity of Kentucky College of MedicineLexingtonKYUSA Department of Molecular and Cellular BiochemistryUniversity of Kentucky College of MedicineLexingtonKYUSA 

出 版 物：《Asian Journal of Urology》 (亚洲泌尿外科杂志（英文）)

年 卷 期：2015年第2卷第1期

页      面：11-18页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by an NIH grant(RO1 DK 083761) 

主　　题：Transforming growth factor-β Prostate tumors Androgen receptor Epithelial-mesenchymal transition Therapeutic value 

摘      要：Few pharmacotherapies are currently available to treat castration resistant prostate cancer(CRPC),with low impact on patient *** growth factor-b(TGF-b)is a multi-functional peptide with opposite roles in prostate tumorigenesis as an inhibitor in normal growth and early stage disease and a promoter in advanced prostate *** TGF-b signaling leads to a cascade of events contributing to oncogenesis,including upregulated proliferation,decreased apoptosis,epithelial-to-mesenchymal transition(EMT)and evasion of immune ***-b signaling pathway presents an appropriate venue for establishing a therapeutic targeting platform in *** of TGF-b effectors and their cross talk with the androgen axis pathway will provide new insights into mechanisms of resistance of the current antiandrogen therapeutic strategies and lead to generation of new effective treatment modalities for *** of functional convergence of TGF-b with key oncogenic pathways,including mitogen-activated protein kinase(MAPK)and androgen receptor(AR),are discussed as navigated within the EMT landscape in the tumor *** this context the emerging anti-TGF-b pharmacotherapies for prostate cancer treatment are *** the functional cross-talk between the TGF-b signaling effectors with the androgen axis supports the development of novel therapeutic strategies for treating CRPC with high specificity and efficacy in a personalized-medicine approach.